AZ licenses kidney drug from Ionis for $330m
February 21, 2018Research and Development, Sales and Marketing AstraZeneca, Ionis, Isis, biotech, drugs, kidney, pharma, pharmaceutical
AstraZeneca continues to build on its relationship with San Diego-based Ionis Pharmaceuticals, this time by agreeing a licensing deal for …
Aimmune’s peanut allergy candidate hits main endpoint at Phase 3
February 21, 2018Research and Development Aimmune, peanut, peanut allergy, pharma
US biopharmaceutical firm Aimmune has revealed that its peanut allergy candidate AR101 hit its primary endpoint in the largest trial …
AbbVie turns to tau for Alzheimer’s in $1.1bn deal
February 21, 2018Research and Development, Sales and Marketing AbbVie, Alzheimer's, Voyager, biotech, drugs, pharma, pharmaceutical
Sailing against the prevailing winds in the Alzheimer’s disease space, AbbVie has launched a deal worth a potential $1.1 billion …
Google develops AI to predict cardiovascular risk
February 21, 2018Research and Development AI, Verily Life Sciences, biotech, cardiovascular, drugs, google, pharma, pharmaceutical
Google and Verily Life Sciences, a subsidiary within Alphabet, focused on developing health-tech, have revealed the fruits of a combined …
NICE recommends thyroid cancer drug trio for NHS use
February 20, 2018Manufacturing and Production, Sales and Marketing Bayer, Cancer, Cometriq, Eisai, Lenvima, NICE, Nexavar, ipsen, pharma, thyroid cancer
NICE has announced its decision to recommend that three separate treatments for thyroid cancer should be made available for use …
Shire, Microsoft and EURORDIS form rare disease alliance
February 20, 2018Manufacturing and Production, Research and Development Microsoft, Shire, eurordis, pharma, rare disease
Rare disease specialist pharma firm Shire, rare disease patient alliance EURORDIS and tech giant Microsoft have announced they have formed …
Low flu vaccine efficacy may be due to previous immune history, study finds
February 20, 2018Manufacturing and Production, Research and Development H3N2, Vaccine, flu, flue vaccine, influenza, pharma
The sometimes poor efficacy of influenza vaccines may be due to poor immune response and a patient’s wider immune history, …
Japan’s Oncolys invests £3m in adenovirus firm Unleash Immuno Oncolytics
February 20, 2018Manufacturing and Production, Research and Development, Sales and Marketing Oncolys, Unleash Immuno Oncolytics, pharma
Unleash Immuno Oncolytics, a US firm focusing on the development of viral biologics in the treatment of cancer, has attracted …
Lilly dumps Hanmi’s rheumatoid arthritis med
February 20, 2018Manufacturing and Production, Sales and Marketing Eli Lilly, arthritis, hanmi, pharma
Eli Lilly and Hanmi signed an exclusive licensing and collaboration agreement to develop the Bruton’s tyrosine kinase (BTK) inhibitor, HM71224, …
Patient experience: Living with multiple myeloma
February 19, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, feature, mutiple myeloma, patient experience, pharma
Pharmafocus talks to John Ellwood about the challenges of being diagnosed with multiple myeloma and how having a strong support …
Apricus shares sink after failed erectile dysfunction application
February 19, 2018Sales and Marketing Apricus, biotech, drugs, pharma, pharmaceutical
Apricus Biosciences had a lot riding on its application to the FDA for its erectile dysfunction cream, Vitaros, with the …
Janssen’s Tremfya shows long-term efficacy in moderate to severe plaque psoriasis
February 19, 2018Research and Development, Sales and Marketing Janssen, Tremfyam guselkumab, pharma, plaque psoriasis, psoriasis
Janssen has unveiled new Phase 3 trial data for its IL-23 inhibitor Tremfya (guselkumab), demonstrating that the drug was able …
Celgene reveals strong P3 Otezla data in rare inflammatory condition
February 19, 2018Research and Development, Sales and Marketing Behçet's disease, Celgene, apremilast, otezla, pharma
Celgene has lifted the curtain on strong new Phase 3 data for its phosphodiesterase 4 (PDE4) inhibitor Otezla (apremilast) in …
Long-running, $2.5bn lawsuit swings in Gilead’s favour
February 19, 2018Sales and Marketing Gilead, MSD, biotech, drugs, harvoni, pharma, pharmaceutical, sovaldi
The fate of pharma company’s profits and losses largely rests on product approvals and the sales team behind them but, …
AZ’s Imfinzi seals blockbuster lung cancer market with FDA nod
February 19, 2018Sales and Marketing AstraZeneca, Imfinzi, biotech, drugs, pharma, pharmaceutical
AstraZeneca’s immunotherapy, Imfinzi, arrived to the industry as a failure – there were big hopes resting on the company’s Mystic …
Top Ten most popular articles on Pharmafile.com this week
February 16, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alzheimer's disease, Roche, Top 10 news, Top ten news, Trump, biotech, drugs, pharma, pharmaceutical
Another week is finished and it’s been a disastrous one for research into a potential treatment for Alzheimer’s disease. Two of …
Ovarian cancer risk may be inherited from the father, research indicates
February 16, 2018Medical Communications, Research and Development Cancer, Roswell Park Comprehensive Cancer Centre, ovarian cancer
Researchers at the Roswell Park Comprehensive Cancer Centre in New York have published findings indicating that ovarian cancer risk may …
FDA weighs up divisive change to Alzheimer’s drug assessment
February 16, 2018Medical Communications Alzheimer's, FDA, biotech, drugs, pharma, pharmaceutical
Alzheimer’s disease (AD) is an area badly in need of a treatment, the problem is that this prospect seems to …
Roche boosts cancer efforts with $1.9 billion buyout of Flatiron Health
February 16, 2018Medical Communications, Sales and Marketing Cancer, Flatiron health, Roche, acquisition, oncology, pharma
Roche has announced it is to acquire privately held healthcare and technology firm Flatiron Health for $1.9 billion to leverage …
Silicon Valley-backed Celgene spin-off launches with $250m
February 16, 2018Medical Communications, Sales and Marketing Celgene, Celularity, biotech, drugs, pharma, pharmaceutical
Biotechs are known for getting off the ground early with serious levels of financing, often based more on the acumen …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
